Articles producció científica> Medicina i Cirurgia

Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study

  • Identification data

    Identifier: PC:2624
    Handle: http://hdl.handle.net/20.500.11797/PC2624
  • Authors:

    Bardají, A.
    Leal, M.
    Arrarte, V.
    Garcia-Moll, X.
    Pérez de Isla, L.
    Bueno, H.
  • Others:

    Author, as appears in the article.: Bardají, A.; Leal, M.; Arrarte, V.; Garcia-Moll, X.; Pérez de Isla, L.; Bueno, H.
    Department: Medicina i Cirurgia
    URV's Author/s: BARDAJÍ RUIZ, ALFREDO; Leal, M.; Arrarte, V.; Garcia-Moll, X.; Pérez de Isla, L.; Bueno, H.
    Keywords: Coronary artery disease Acute coronary syndrome myocardial infarction
    Abstract: Introduction: Real-world, country-specific studies of dual antiplatelet therapy (DAPT) duration among survivors of acute coronary syndrome (ACS) are important for improving long-term prognosis. Aims: To investigate DAPT duration after hospital discharge for ACS in Spain. Results: Data from patients enrolled in the Spanish cohort of the EPICOR (long-tErm follow-up of antithrombotic management Patterns In acute CORonary syndrome patients) study (NCT01171404) were analyzed for changes to antithrombotic medication up to 2 years postdischarge according to index event diagnosis and patient characteristics. Deaths, coronary events, and bleeding events were analyzed over the same period. Overall, a high proportion of patients remained on DAPT at 2 years (53.1%). Among patients who experienced any on-treatment bleeding event, almost two-thirds remained on DAPT at the end of follow-up. Patients >65 years, diabetic, or those that were medically managed were more likely to continue with DAPT until 2 years following discharge. At 2 years, the incidence of bleeding events requiring hospitalization was low compared with the incidence of coronary events (1.4% vs 6.6%). There was a numerical reduction in coronary events, but no increase in bleeding events, with DAPT continuation compared with single antiplatelet therapy. Conclusions: More than half of patients in this unselected cohort study remained on DAPT at 2 years following discharge for ACS. Continuation with DAPT was greater among patients with additional cardiovascular risk factors, which suggests that treating physicians in Spain prioritizes ischemic risk reduction over bleeding risk in patients with ACS, according to patient's risk profile.
    Research group: Grup de Recerca Biomèdica HJ23
    Thematic Areas: Health sciences Ciencias de la salud Ciències de la salut
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 1755-5914
    Author identifier: N/D; N/D; N/D; N/D; N/D; N/D
    Record's date: 2017-03-28
    Journal volume: 35
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://onlinelibrary.wiley.com/doi/full/10.1111/1755-5922.12237
    Article's DOI: 10.1111/1755-5922.12237
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2017
    First page: Art.num. e12237
    Publication Type: Article Artículo Article
  • Keywords:

    Infart de miocardi
    Artèries coronàries -- Malalties
    Malalties coronàries
    Coronary artery disease
    Acute coronary syndrome
    myocardial infarction
    Health sciences
    Ciencias de la salud
    Ciències de la salut
    1755-5914
  • Documents:

  • Cerca a google

    Search to google scholar